NovaBay Appoints CEO Justin Hall to its Board of Directors

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the appointment of President and CEO Justin Hall to the Company’s board of directors, effective August 21, 2020. Mr. Hall has been with NovaBay for seven years in various capacities, and fills a vacancy on the board following the resignation of Xiaopei (Ray) Wang. Board membership remains at six, including three independent directors.

Mr. Hall will serve as a Class II director, and will stand for reelection to a three-year term at the 2021 NovaBay annual meeting of stockholders.

“Serving as chief executive for the past 18 months, Justin has proven to be a highly capable leader who is well respected by the NovaBay staff and business partners,” said NovaBay Chairman of the Board Paul E. Freiman. “He successfully spearheaded a major shift in U.S. commercial strategy to broaden sales of our flagship product, Avenova, from prescription only to include the direct to consumer channel. Online unit sales have subsequently become an increasing portion of our core business, with consumers continuing to have access to our product during the COVID-19 pandemic without interruption and without leaving their homes.

“He tapped our international health network early in the U.S. pandemic for personal protective equipment when supply of these important items was severely limited. More recently, he led efforts to secure funding and improve our capital structure, providing our Company with financial security during these uncertain times. The board acknowledges his leadership and welcomes his membership. On behalf of the board, I would also like to extend sincere thanks to Ray for his service over the past two years,” added Mr. Freiman.

“It’s exciting to take this next step at NovaBay as we navigate the pandemic while moving toward future growth,” said Mr. Hall. “I see significant opportunities ahead to build on our current business with new products and expanded markets. I have developed a close working relationship with the board over my years with the Company, and appreciate their confidence.”

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX family of products and the AGANOCIDE compounds. The Neutrox family of products includes AVENOVA for the eye care market, CELLERX for the aesthetic dermatology market and NEUTROPHASE for the wound care market. The Aganocide compounds, still under development, have target applications in dermatology and urology.